Last reviewed · How we verify
NCT07343349: DAPROCA10
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
NA trial testing Addition of focal boost and hypofractionation in Prostate Cancer Patients Undergoing External Radiation and Seed Implantation in 1,016 participants. Currently enrolling.
30 October 2040
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,016 |
| Start date | 15 December 2025 |
| Primary completion | 30 October 2040 |
| Estimated completion | 30 October 2040 |
| Sites | 3 locations across Denmark |
Drugs / interventions tested
- Addition of focal boost and hypofractionation
Conditions studied
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation — all drugs for Prostate Cancer Patients Undergoing External Radiation and Seed Implantation →
- High Risk Localised Prostate Carcinoma — all drugs for High Risk Localised Prostate Carcinoma →
- Locally Advanced Prostate Cancer — all drugs for Locally Advanced Prostate Cancer →
- Unfavourable Intermediate Risk Prostate Cancer — all drugs for Unfavourable Intermediate Risk Prostate Cancer →
Sponsor
Rigshospitalet, Denmark
Who can join
18 and older, male only, with Prostate Cancer Patients Undergoing External Radiation and Seed Implantation or High Risk Localised Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and globally. The aim is to reduce later cancer spreading, need of hormone treatments and prostate cancer death. DAPROCA 10 tests two possible improvements: If a higher dose (boost) to intra-prostatic tumor lesions improves cure rates. If the radiotherapy can be given with 12 treatment fractions instead of 20 without increased side-effects. In this randomised trial half the participants get a boost and the other half don't. Half the patients get 12 treatments, the other half 20. To answer these questions we must include1016 participants. The trial is feasible because the technological advances in imaging and radiotherapy enables us to define the tumors in the prostate and to deliver the boost to the tumors with high precision, without increased dose to the surrounding organs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07343349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07343349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07343349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing